Applicants: Mark Ledeboer et al.
Application No.: 10/657,811

AMENDMENTS TO THE CLAIMS

Please replace all prior versions and listings of claims with the amended claims as follows:

1. (Currently amended) A compound of formula [[I]] II or III:



I



II



III

or a pharmaceutically acceptable salt thereof,

wherein:

$R^1$ is hydrogen or fluorine ~~halogen~~.

~~$R^2$ is substituted or unsubstituted cycloalkyl;~~

each occurrence of $R^3$ is independently alkyl, -OH, $-CH_2OH$ or alkoxy ~~halogen, alkyl, $-(CH_2)_mOR^4$, $-(CH_2)_mSR^4$, $-(CH_2)_mN(R^4)_2$, $-(CH_2)_mNR^4C(O)R^4$, $-(CH_2)_mNR^4C(O)N(R^4)_2$, $-(CH_2)_mNR^4CO_2R^4$, $-(CH_2)_mCO_2R^4$, $-(CH_2)_mC(O)R^4$, $-(CH_2)_mC(O)N(R^4)_2$, $-(CH_2)_mOC(O)N(R^4)_2$, $-(CH_2)_mS(O)_2R^4$, $-(CH_2)_mSO_2N(R^4)_2$,~~

Applicants: Mark Ledeboer et al.
Application No.: 10/657,811

~~$(CH_2)_mS(O)R^4$, $(CH_2)_mNR^4SO_2N(R^4)_2$, $(CH_2)_mNR^4SO_2R^4$, $(CH_2)_mC(=S)N(R^4)_2$, wherein m is 0, 1 or 2 and $R^4$ is hydrogen or alkyl~~;

r is 0 or [[,]] 1 ~~or 2~~; ~~and~~

each occurrence of $R^5$ is independently -OH or alkyl;

p is 0 or 1; and

n is 0, 1 or 2.

2-4. (Canceled)

5. (Original) The compound of claim 1, wherein $R^1$ is F.

6. (Original) The compound of claim 1, wherein $R^1$ is H.

7. (Canceled)

8. (Original) The compound of claim 1, wherein n is 0.

9. (Original) The compound of claim 1, wherein n is 1.

10. (Original) The compound of claim 1, wherein n is 2.

11-14. (Canceled)

15. (Currently amended) The compound of claim 1 ~~3 or 4~~, wherein p is [[0 or]] 1 ~~and $R^5$ is OH, or alkyl~~.

16. (Currently amended) The compound of claim 1 [[3]], wherein ~~$R^1$ is F or H;~~ p is 0~~; n is 0 or 1; r is 0 or 1; and $R^3$ is OH, $CH_2OH$, alkyl or alkoxy~~.

Applicants: Mark Ledeboer et al.
Application No.: 10/657,811

17. (Currently amended) The compound of claim 1 [[4]], wherein ~~$R^1$ is F or H; p is 0, 1 or 2; each occurrence of $R^5$ is independently alkyl, OH, $CH_2OH$ or alkoxy; n is 0 or 1;~~ r is [[0 or]] 1~~; and $R^3$ is OH, $CH_2OH$, alkyl or alkoxy~~.

18. (Currently amended) The compound of claim 1, wherein the compound has one of the following structures:



I-1



I-2



I-3



I-4



I-5



I-6

Applicants: Mark Ledeboer et al.
Application No.: 10/657,811



I-7



I-8



I-9



I-10



I-11



I-12



I-13



I-14

Applicants: Mark Ledeboer et al.
Application No.: 10/657,811



**I-15**



~~**I-16**~~



**I-17**



**I-18**



**I-19**



**I-20**

19. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

20. (Currently amended) The composition according to claim 19, further comprising an additional therapeutic agent that is ~~selected from~~ a treatment for stroke, ~~a treatment for Alzheimer's Disease, a treatment for Parkinson's Disease, an agent for treating Multiple Sclerosis (MS), a treatment for asthma, an agent for treating schizophrenia, an anti-inflammatory agent, an immunomodulatory or~~

~~immunosuppressive agent, a neurotrophic factor, an agent for treating cardiovascular disease, or an agent for treating an immunodeficiency disorder~~.

21. (Currently amended) A method of treating a ~~neurodegenerative, neurological,~~ ischemic or inflammatory disorder of the central nervous system comprising administering a therapeutically effective amount of a compound of claim 1.

22. (Original) The method according to claim 21, wherein the ischemic disorder is stroke.

23. (Currently amended) The method according to claim 22, comprising the further step of:

administering to said patient an additional therapeutic agent that is ~~selected from~~ a treatment for stroke, ~~a treatment for Alzheimer's Disease, a treatment for Parkinson's Disease, an agent for treating Multiple Sclerosis (MS), a treatment for asthma, an agent for treating schizophrenia, an anti-inflammatory agent, an immunomodulatory or immunosuppressive agent, a neurotrophic factor, an agent for treating cardiovascular disease, or an agent for treating an immunodeficiency disorder~~ wherein:

said additional therapeutic agent is appropriate for the disease being treated; and

said additional therapeutic agent is administered together with said composition as a single dosage form or separately from said composition as part of a multiple dosage form.